Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 6 1 2022
medline: 12 4 2022
entrez: 5 1 2022
Statut: ppublish

Résumé

Radical cystectomy (RC) with urinary diversion (UD) is still considered a complex surgery associated with significant morbidity. Open RC (ORC) remains the reference option of treatment, even if adoption of robot-assisted RC (RARC) is rapidly increasing. To date, all the available randomized controlled trials were characterized by an extracorporeal approach in performing UD, undermining potential benefits of a totally minimally invasive procedure. In this study, we aimed to report perioperative and 6-month outcomes from the first RCT comparing ORC and RARC with totally intracorporeal UD. Patients were eligible for randomization if they had a diagnostic transurethral resection of bladder tumor with cT2-4, cN0, cM0 or recurrent high-grade nonmuscle-invasive bladder cancer and no anesthesiological contraindications to robotic surgery. Patients were enrolled with a covariate adaptive randomization process based on the following variables: body mass index, American Society of Anesthesiologists® score, baseline hemoglobin, planned UD, neoadjuvant chemotherapy and cT stage. The primary end point was to demonstrate the superiority of RARC with intracorporeal UD in terms of a 50% transfusion rate reduction. Overall, 116 consecutive patients (58 RARC, 58 ORC) were enrolled. Among primary endpoint, overall perioperative transfusion rates were significantly lower in the RARC cohort (RARC: 22% vs ORC: 41%; p=0.046). This prospective randomized trial observed 22% and 41% overall perioperative transfusion rates in patients treated by RARC and ORC, respectively, confirming a significant benefit in favor of RARC with intracorporeal UD. However, perioperative complications, hospital stay and 6-month health-related quality of life were largely comparable between groups. Oncologic and functional outcomes will be assessed at longer followup to observe potential differences between arms.

Identifiants

pubmed: 34986007
doi: 10.1097/JU.0000000000002422
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

982-992

Commentaires et corrections

Type : CommentIn

Auteurs

Riccardo Mastroianni (R)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Mariaconsiglia Ferriero (M)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Gabriele Tuderti (G)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Umberto Anceschi (U)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Alfredo Maria Bove (AM)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Aldo Brassetti (A)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Leonardo Misuraca (L)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Ashanti Zampa (A)

IRCCS "Regina Elena" National Cancer Institute, Department of Clinical Trial Centre, Biostatistics and Bioinformatics, Rome, Italy.

Giulia Torregiani (G)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Edoardo Ghiani (E)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Diana Giannarelli (D)

IRCCS "Regina Elena" National Cancer Institute, Department of Clinical Trial Centre, Biostatistics and Bioinformatics, Rome, Italy.

Salvatore Guaglianone (S)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Michele Gallucci (M)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Giuseppe Simone (G)

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH